Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-24T17:04:23.248Z Has data issue: false hasContentIssue false
  • English
  • Français

Pregabalin for the treatment of generalized anxiety disorder

Published online by Cambridge University Press:  01 September 2022

A. Khallouk ,
A. Rhaouti ,
A. Boukdir ,
S. Stati ,
H. Nafiaa  and
A. Ouanass
A. Khallouk*
Affiliation:
University Psychiatric Hospital Ar-razi, university hospital center, SALE, Morocco, University Of Mohammed V, Rabat,, salé, Morocco
A. Rhaouti
Affiliation:
University Psychiatric Hospital Ar-razi, university hospital center, SALE, Morocco, University Of Mohammed V, Rabat,, salé, Morocco
A. Boukdir
Affiliation:
University Psychiatric Hospital Ar-razi, university hospital center, SALE, Morocco, University Of Mohammed V, Rabat,, salé, Morocco
S. Stati
Affiliation:
hopital arrazi de sale, Psychiatrie, sale, Morocco
H. Nafiaa
Affiliation:
university hospital center, University Psychiatric Hospital Ar-razi, SALE, Morocco
A. Ouanass
Affiliation:
Hôpital psychiatrique ARRAZI de Salé, Psychiatrie, Salé, Morocco
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Pregabalin is a treatement with a complexe mechanism of action. It’s an antiepileptic drug used as adjunctive treatment of partial epilepsy, it is also taken in the treatment of neuropathic pain, and generalized anxiety disorder, in addition to epilepsy. Some of the advantages of pregabalin include. pharmacokinetics, safety, and tolerability. Clinical trials have demonstrated the efficacy of pregabalin comparable to benzodiazepines, without risk of abuse.

Objectives

to assess the efficacy of pregabalin in patients with generalized anxiety disorder in the Ar-Razi university psychiatric hospital in Salé in Morocco

Methods

To assess the place of pregabalin in the treatement of anxiety disorders through patients hospitalized in the Ar-Razi university psychiatric hospital in Salé in Morocco The evaluation instruments are: For anxiety the Hamilton Anxiety Scale and For therapeutic efficacy CGI-therapeutic index

Results

based on the results of our study on the patients who have improved after an optimal duration of treatment, in conjunction with psychological monitoring, we retain that pregabalin can significantly improve the quality of life of anxious patients and also guarantee them a better prognosis

Conclusions

Pregabalin was significantly more efficacious for the treatment of psychic and somatic symptoms of generalized anxiety disorder and was well tolerated by most study patients.

Disclosure

No significant relationships.

Keywords

disorderTreatmentAnxietypregabalin
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S399
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.